Earkart Limited Completes Postal Ballot Notice Dispatch for IPO Proceeds Reallocation
Earkart Limited has completed the dispatch of its postal ballot notice through newspaper advertisements in Financial Express and Jansatta, seeking shareholder approval to reallocate ₹1304.69 lakhs from its IPO proceeds towards new pharmaceutical initiatives and strategic acquisitions. The e-voting process runs from April 02 to May 01, 2026, requiring approval from more than 90% of voting shareholders.
*this image is generated using AI for illustrative purposes only.
Earkart Limited has completed the dispatch of its postal ballot notice seeking shareholder approval for significant changes in the utilization of its Initial Public Offering (IPO) proceeds. The company has published newspaper advertisements in Financial Express (English) and Jansatta (Vernacular) on April 02, 2026, confirming the completion of notice dispatch to eligible shareholders.
Proposed Fund Reallocation Structure
The company originally raised net proceeds of ₹3906.79 lakhs through its IPO and now seeks to modify the deployment strategy. The proposed reallocation involves shifting ₹1304.69 lakhs from the Shop-in-Shop (SIS) business model expansion to new business verticals.
| Object of Issue: | Original Allocation (₹ lakhs) | Proposed Allocation (₹ lakhs) | Variation (₹ lakhs) |
|---|---|---|---|
| Working Capital Requirements: | 2110.13 | 2610.13 | +854.69 |
| SIS Business Model & Infrastructure: | 1733.26 | 383.26 | -1304.69 |
| General Corporate Purposes: | 63.40 | 63.40 | - |
| Pharmaceutical Business (New): | - | 250.00 | +250.00 |
| Acquisitions (New): | - | 600.00 | +600.00 |
| Total: | 3906.79 | 3906.79 | - |
New Business Initiatives
Pharmaceutical Division: The company plans to allocate ₹250.00 lakhs towards pharmaceutical initiatives, including strategic acquisitions of hospitals, clinics, and pharmaceutical businesses. This expansion aligns with the company's objective of strengthening its presence in the healthcare and pharmaceutical sector.
Strategic Acquisitions: An allocation of ₹600.00 lakhs has been proposed for acquiring land, properties, and complementary businesses. The company intends to explore acquisitions in healthcare services, pharmaceutical distribution, medical products, and related areas to enhance operational capabilities and geographic presence.
Enhanced Working Capital: The working capital allocation increases from ₹2110.13 lakhs to ₹2610.13 lakhs, with the additional ₹854.69 lakhs supporting the company's existing business operations and SIS model expansion.
E-Voting Process and Timeline
The postal ballot is being conducted exclusively through remote e-voting, with no physical ballot forms being dispatched. The company has engaged National Securities Depository Limited (NSDL) to provide e-voting facilities, with M/s. Nikita Kothari & Associate appointed as the scrutinizer.
| Event: | Date and Time |
|---|---|
| Cut-off Date for Voting Eligibility: | March 20, 2026 |
| E-voting Commencement: | April 02, 2026, 09:00 a.m. (IST) |
| E-voting End: | May 01, 2026, 05:00 p.m. (IST) |
| Results Declaration: | On or before May 03, 2026 |
Regulatory Compliance and Communication
Pursuant to Regulation 30 and 47(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company has notified BSE Limited about the completion of postal ballot notice dispatch. The notice has been made available on the company's website at www.earkart.in .
Shareholders whose email addresses are registered with the company or depositories have received the postal ballot notice electronically. The proposed variation requires approval from more than 90% of shareholders voting through the remote e-voting process.
Board Approval and Risk Assessment
The Board of Directors unanimously approved the proposed variation at its meeting held on March 30, 2026, with no directors voting against the resolution. The company has identified several risk factors associated with the new initiatives, including regulatory compliance challenges in the pharmaceutical sector, market competition, acquisition-related risks, and integration complexities.
The company expects the proposed changes to enhance profitability, improve cash flows, and strengthen its overall market position in the healthcare ecosystem.
What specific pharmaceutical companies or healthcare assets is Earkart targeting for acquisition with its ₹850 lakh allocation?
How will Earkart's shift away from the Shop-in-Shop model affect its competitive position in the retail sector?
What regulatory approvals will Earkart need to secure before entering the pharmaceutical business, and what timeline is expected?
20
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
